

COMPANY

Stromedix is a clinical-stage biotechnology company developing novel drugs to treat fibrosis and fibrotic organ failure. Our lead program, STX-100, has recently completed a Phase 1 clinical trial.

Stromedix is lead by a team of seasoned biotechnology industry veterans with deep experience in drug development. The company has also created a strong network of medical and scientific advisers. The company is focused initially on chronic organ failure but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

FIBROSIS AND CHRONIC ORGAN FAILURE

Fibrosis results from the body's attempt to repair chronic tissue injury. Ongoing cycles of injury and repair, often playing out over decades, lead to accumulation of scar tissue in affected organs and disruption of normal tissue architecture and function. In short, the organ fails. Fibrosis is the final common pathway in virtually all forms of chronic organ failure — including kidney, liver, lung and heart failure. Moreover, the biology of fibrosis is similar, regardless of cause — viral, chemical, physical or inflammatory.

Fibrosis results from the excessive activity of fibroblasts, in particular a differentiated form known as the myofibroblast. The biology of these cells is well understood and scientists believe that drugs that attenuate myofibroblast activity ought to slow or perhaps even reverse the progression of fibrosis, restoring organ function and prolonging healthy life.

Fibrotic organ failure affects more than twenty million people in the US alone.

THERAPEUTIC PIPELINE

STX-100 is a humanized monoclonal antibody targeting integrin $\alpha v \beta 6$. Originally developed at and licensed from Biogen Idec, STX-100 exhibits significant anti-fibrotic activity in preclinical models of lung, kidney and liver disease and cancer. Stromedix is currently developing STX-100 for the treatment of interstitial fibrosis and tubular atrophy in kidney transplant recipients and for idiopathic pulmonary fibrosis (IPF).

Stromedix believes that STX-100 may have therapeutic utility in a broad array of chronic organ failure settings, acute organ failure and cancer.

The company has completed a Phase 1 study for STX-100 and is planning Phase 2a trials in kidney transplant and IPF patients in 2010.

MANAGEMENT

Michael Gilman, Ph.D.
Founder and Chief Executive Officer

Brad Maroni, M.D.
Chief Medical Officer

Shelia Violette, Ph.D.
Vice President, Research


Daniel Lynch
Executive Chairman

INVESTORS

Stromedix has raised \$29.4 million from an outstanding syndicate of investors, including Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Frazier Healthcare Ventures, and Red Abbey Venture Partners. Biogen Idec is also a shareholder.

CONTACT

For more information, please visit our website, call or write us at info@stromedix.com.



**One Canal Park, Suite 1120
Cambridge, MA 02141
Tel: +1 (617) 674-8400
Fax: +1 (617) 674-8390
www.stromedix.com**